Skip to main content Back to Top
Advertisement

9/3/2019

Dobutamine Injection

Products Affected - Description

    • Dobutamine injection, Pfizer, 12.5 mg/mL, 20 mL latex-free vial, 10 count, NDC 00409-2025-20
    • Dobutamine injection, Pfizer, 12.5 mg/mL, 40 mL latex-free vial, 10 count, NDC 00409-2025-54
    • Dobutamine injection, Pfizer, 4 mg/mL, 250 mL premixed bag, 12 count, NDC 00409-3724-32

Reason for the Shortage

    • Baxter has dobutamine available.
    • Pfizer has dobutamine on shortage due to manufacturing delays.

Available Products

    • Dobutamine injection, Baxter, 1 mg/mL, 250 mL premixed bag, 12 count, NDC 00338-1073-02
    • Dobutamine injection, Baxter, 2 mg/mL, 250 mL premixed bag, 12 count, NDC 00338-1075-02
    • Dobutamine injection, Baxter, 4 mg/mL, 250 mL premixed bag, 12 count, NDC 00338-1077-02
    • Dobutamine injection, Pfizer, 1 mg/mL, 250 mL premixed bag, 12 count, NDC 00409-2346-32
    • Dobutamine injection, Pfizer, 12.5 mg/mL, 20 mL vial, 1 count, NDC 00409-2344-01
    • Dobutamine injection, Pfizer, 12.5 mg/mL, 20 mL vial, 10 count, NDC 00409-2344-02
    • Dobutamine injection, Pfizer, 2 mg/mL, 250 mL premixed bag, 12 count, NDC 00409-2347-32

Estimated Resupply Dates

    • Pfizer has dobutamine 12.5 mg/mL 20 mL and 40 mL latex-free vials on back order with an estimated release date of March 2020 for the 20 mL vials and December 2019 for the 40 mL vials.
    • Pfizer has dobutamine 4 mg/mL in 250 mL bags on back order and the company estimates a release date of September 2019.

Updated

Updated September 3, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created March 1, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins